title: Simvastatin enhances irinotecan-induced apoptosis in human non-small cell lung cancer cells by inhibition of proteasome activity.
abstract: Simvastatin, a potent inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) is known to stimulate apoptotic cell death and induce cell cycle arrest through inhibition of proteasome. The purpose of this study is to investigate whether simvastatin would be synergistic with irinotecan against human non-small cell lung cancer (NSCLC) cells. Antitumor effect was measured by growth inhibition of cells and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The cytotoxic interaction between irinotecan and simvastatin was assessed using the combination index. Effects on cell cycle distribution and apoptosis were determined by flow cytometry and DNA fragmentation. Proteasome activity was measured by ELISA quantification of 20S proteasome. NF-κB activation was determined using TransAM™ NF-κB p65 Transcription Factor Assay Kit. IκB-α was measured by immunoblot. A combination of irinotecan with simvastatin showed significantly enhanced cell growth inhibition compared with irinotecan alone, which resulted in a synergistic cytotoxicity. Irinotecan and simvastatin combination treatment of A549 and H460 cells increased G(1) phase arrest, which was associated with up-regulation of p21(WAF1/CIP) and p53 compared with irinotecan alone. In addition, simvastatin combination treatment increased irinotecan-related apoptosis as determined by fluorescence microscopy and flow cytometric analysis. We also found that combination therapy showed superior proteasome inhibitory activity leading to effectively suppress NF-κB transcription factor activation. Consistently, this effect was associated with up-regulation of IκB-α. These findings suggest that simvastatin enhances irinotecan-induced apoptosis in human NSCLC cells through inhibition of proteasome activity.
authors.affiliation: Lung Cancer Branch, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
authors.forename: In Hae
authors.initials: IH
authors.lastname: Park
authors.forename: Jin Young
authors.initials: JY
authors.lastname: Kim
authors.forename: Ji Young
authors.initials: JY
authors.lastname: Choi
authors.forename: Ji-Youn
authors.initials: JY
authors.lastname: Han
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D001562:Benzimidazoles / Q000378:metabolism; D015153:Blotting, Western; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002289:Carcinoma, Non-Small-Cell Lung / Q000201:enzymology / Q000473:pathology*; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D005434:Flow Cytometry; D006801:Humans; D020672:I-kappa B Proteins / Q000378:metabolism; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology*; D000072000:NF-KappaB Inhibitor alpha; D016328:NF-kappa B / Q000378:metabolism; D046988:Proteasome Endopeptidase Complex / Q000378:metabolism; D061988:Proteasome Inhibitors; D019821:Simvastatin / Q000494:pharmacology*; D013194:Staining and Labeling; D013379:Substrate Specificity / Q000187:drug effects
chemical_list: D001562:Benzimidazoles; D020672:I-kappa B Proteins; D016328:NF-kappa B; C000606204:NFKBIA protein, human; D061988:Proteasome Inhibitors; D000072000:NF-KappaB Inhibitor alpha; D000077146:Irinotecan; D019821:Simvastatin; D046988:Proteasome Endopeptidase Complex; C017807:bisbenzimide ethoxide trihydrochloride; D002166:Camptothecin
references.citation: Eur J Haematol. 2007 Sep;79(3):240-3
references.pmid: 17655704
references.citation: Clin Cancer Res. 2002 Mar;8(3):641-61
references.pmid: 11895891
references.citation: Oncologist. 2001;6(1):66-80
references.pmid: 11161230
references.citation: Oncogene. 1998 Nov 5;17(18):2393-402
references.pmid: 9811471
references.citation: Clin Cancer Res. 2008 Mar 15;14(6):1649-57
references.pmid: 18347166
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1819-25
references.pmid: 17179483
references.citation: Leukemia. 2002 Apr;16(4):508-19
references.pmid: 11960327
references.citation: J Biol Chem. 2000 Mar 31;275(13):9501-9
references.pmid: 10734098
references.citation: J Natl Cancer Inst. 2007 Jan 3;99(1):32-40
references.pmid: 17202111
references.citation: Clin Cancer Res. 2005 Mar 15;11(6):2398-407
references.pmid: 15788691
references.citation: Nature. 1990 Feb 1;343(6257):425-30
references.pmid: 1967820
references.citation: J Biol Chem. 1999 Jul 30;274(31):21926-31
references.pmid: 10419514
references.citation: Science. 2001 May 11;292(5519):1160-4
references.pmid: 11349148
references.citation: J Immunol. 2007 Feb 15;178(4):2507-16
references.pmid: 17277159
references.citation: Nat Rev Cancer. 2005 Dec;5(12):930-42
references.pmid: 16341084
references.citation: Cancer Sci. 2004 May;95(5):464-8
references.pmid: 15132777
references.citation: Cancer Cell. 2004 May;5(5):417-21
references.pmid: 15144949
references.citation: Cancer. 2006 Dec 1;107(11):2688-97
references.pmid: 17075878
references.citation: Nat Med. 1999 Apr;5(4):412-7
references.pmid: 10202930
references.citation: Biochem Pharmacol. 2008 Feb 15;75(4):907-13
references.pmid: 18036510
references.citation: N Engl J Med. 2003 Jun 26;348(26):2597-8
references.pmid: 12826633
references.citation: Proc Natl Acad Sci U S A. 1999 Jul 6;96(14):7797-802
references.pmid: 10393901
references.citation: N Engl J Med. 2006 Dec 21;355(25):2705-7
references.pmid: 17183004
references.citation: Oncogene. 2005 May 26;24(23):3786-96
references.pmid: 15782134
references.citation: J Natl Cancer Inst. 1994 Oct 19;86(20):1517-24
references.pmid: 7932806